title: Elevated serum levels of CXCL9/monokine induced by interferon-gamma and CXCL10/interferon-gamma-inducible protein-10 in ocular sarcoidosis.
abstract: OBJECTIVE
  Sarcoidosis is a chronic multisystem granulomatous disorder characterized by an accumulation of activated CD4+ T cells and monocytes/macrophages in involved organs. Chemokines are required for the extravasation of leukocytes to the inflammation site. This study was undertaken to determine which chemokines are augmented in the serum of patients with active ocular sarcoidosis.
  
  
  METHODS
  Seventeen patients with diagnosed ocular sarcoidosis, 28 with suspected ocular sarcoidosis, 16 with Behçet's disease, 17 with Vogt-Koyanagi-Harada disease, and 18 healthy subjects were studied. Serum levels of CCL2, CCL5, CXCL8, CXCL9, and CXCL10 were simultaneously measured by cytometric bead array using flow cytometer. In addition, serum CXCL9 and CXCL10 levels in the patients with diagnosed or suspected ocular sarcoidosis were compared with respect to ocular disease activity, the presence of bilateral hilar lymphadenopathy (BHL), and laboratory data.
  
  
  RESULTS
  Serum levels of both CXCL9 and CXCL10 were markedly elevated in the patients with diagnosed or suspected ocular sarcoidosis compared with patients with other types of uveitis and healthy subjects. Although CCL2 and CXCL8 were detected in the serum of all subjects, the levels were extremely low with no significant differences between groups. Elevation of serum CXCL9 and CXCL10 in ocular sarcoidosis correlated significantly with ocular disease activity and ACE (angiotensin converting enzyme) levels and was unrelated to the presence of BHL, erythrocyte sedimentation rate, white blood cell count, serum IgG, or serum lysozyme.
  
  
  CONCLUSIONS
  The results demonstrated that serum levels of CXCL9 and CXCL10 were elevated markedly in the patients with ocular sarcoidosis and correlated with ocular disease activity and ACE level.
authors.affiliation: Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan. takeuchi@tokyo-med.ac.jp
authors.forename: Masaru
authors.initials: M
authors.lastname: Takeuchi
authors.forename: Keiko
authors.initials: K
authors.lastname: Oh-I
authors.forename: Jun
authors.initials: J
authors.lastname: Suzuki
authors.forename: Takaaki
authors.initials: T
authors.lastname: Hattori
authors.forename: Aya
authors.initials: A
authors.lastname: Takeuchi
authors.forename: Yoko
authors.initials: Y
authors.lastname: Okunuki
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Usui
authors.forename: Masahiko
authors.initials: M
authors.lastname: Usui
mesh_terms: D000328:Adult; D000368:Aged; D001528:Behcet Syndrome / Q000097:blood; D018932:Chemokine CCL2 / Q000097:blood; D018946:Chemokine CCL5; D054357:Chemokine CXCL10; D054370:Chemokine CXCL9; D019742:Chemokines, CC / Q000097:blood; D019743:Chemokines, CXC / Q000097:blood*; D005128:Eye Diseases / Q000097:blood*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000097:blood; D013902:Radiography, Thoracic; D012507:Sarcoidosis / Q000097:blood*; D014607:Uveomeningoencephalitic Syndrome / Q000097:blood
chemical_list: C111835:CCL2 protein, human; C483024:CCL5 protein, human; C114753:CXCL10 protein, human; C080810:CXCL9 protein, human; D018932:Chemokine CCL2; D018946:Chemokine CCL5; D054357:Chemokine CXCL10; D054370:Chemokine CXCL9; D019742:Chemokines, CC; D019743:Chemokines, CXC; D036341:Intercellular Signaling Peptides and Proteins; D007703:Peptidyl-Dipeptidase A